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Purpose: To evaluate the predictive performance of various parameters derived from volume-adjusted prostate-specific antigen (PSA) 
values in detecting prostate cancer (PCa) and high-grade (Gleason score≥7) PCa according to treatment with a 5α-reductase inhibitor 
(5ARI).
Methods: The results of 3,520 prostate biopsies performed between May 2006 and January 2013 were retrospectively assessed. 
With adjustment for age, 291 patients who had received 5ARI treatment for more than 6 months were identified and matched 1:3 to 
patients naïve to 5ARIs, resulting in a total of 873 patients. Peripheral zone (PZ) and transition zone (TZ) volumes were determined by 
transrectal ultrasonography. Receiver-operating characteristic (ROC) curve analysis was used to compare predictive performances of 
PSA, PSA density (PSAD; PSA/prostate volume), PZPSAD (PSA/PZ volume), and TZPSAD (PSA/TZ volume) for detecting PCa and high-
grade PCa for each group.
Results: The area under the ROC curve (AUC) was higher for PSAD than for PSA in the 5ARI group (0.751 vs. 0.677) and in the 5ARI-
naïve group (0.649 vs. 0.582), respectively (P <0.001). In the 5ARI group, the AUC for PZPSAD was even higher than that for PSAD (0.781 
vs. 0.751, P =0.038); in the 5ARI-naïve group, however, PZPSAD failed to achieve significant superiority (0.652 vs. 0.649, P =0.321). All 
volume-adjusted PSA indexes showed higher predictive accuracies for detecting PCa than did PSA in both groups. For detecting high-
grade cancer, PZPSAD also revealed the highest predictive value in the 5ARI group, whereas PSA revealed the highest predictive value 
in the 5ARI-naïve group.
Conclusions: The diagnostic performance of PSAD in the detection of PCa is superior to that of PSA. For patients receiving 5ARI for 
more than 6 months, PZPSAD confers additional benefits for detecting both PCa and high-grade PCa.
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INTRODUCTION
Prostate cancer (PCa) is the most common solid organ malig-
nancy and the second most common cause of cancer-related 
death among men in industrialized nations [1]. Prostate-specific 
antigen (PSA) is the most widely used serum marker that has 
revolutionized the early detection and management of PCa 
[2,3]. However, the relative lack of cancer-specificity, without 
upper or lower threshold values, is a major drawback that 
may lead to unnecessary risks and costs [1].
 Various attempts have been made to overcome these 
limitations, namely, the utilization of PSA density (PSAD), 
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derwent 12-core to 14-core prostate biopsy. Patients with 
inadequate transrectal ultrasonography (TRUS) images with 
an ambiguous boundary between the peripheral zone (PZ) 
and the TZ, an indefinite history of prior medications, or a 
pathological diagnosis of prostatic intraepithelial neoplasia 
or atypical small acinar proliferation were excluded from the 
study cohort. Patients who had received 5ARIs for more than 
6 months were identified and designated as group A. Each 
group A patient was randomly matched with three patients 
naïve to 5ARIs with adjustment for age, who were designated 
as group B. The study was carried out in accordance with the 
Institutional Review Board practice guidelines.
2. Measurements of PSAD-based parameters
TRUS was used to measure the total PV and the TZ volume 
(TZV) by use of the formula for a prolate ellipsoid (length ×  
width × height × 0.52). The PZ volume (PZV) was measured by 
subtracting TZV from PV. PSAD, PZPSAD, and TZPSAD were 
calculated by dividing PSA by PV, PZ, and TZ, respectively.
3. Statistical analysis
Comparisons between groups were performed by using Stu-
dent t-test. Areas under the ROC curves (AUCs) were used to 
calculate performances of PSA, PSAD, PZPSAD, and TZPSAD 
in detecting PCa and high-grade disease, defined as a Glea-
son score sum ≥ 7. Pairwise comparisons of ROC curves were 
used to compare predictive performances between each 
volume-adjusted PSA parameter. All statistical analyses were 
performed by using IBM SPSS ver. 18.0 (IBM Co., Armonk, 
NY, USA) and MedCalc ver. 11.6 (MedCalc Software, Aca-
cialaan, Ostend, Belgium). Statistical significance was set at 
P < 0.05.
percentage of free PSA, PSA velocity, age-specific PSA ranges, 
complex PSA, and transition zone (TZ) PSAD [4-6]. However, 
none of these indexes has achieved satisfactory results ap-
plicable to everyday clinical practice. The interpretation of 
PSA is even more complex in patients with benign prostatic 
hyperplasia who are administered 5α-reductase inhibitors 
(5ARIs). 5ARIs have been shown to reduce prostate volume 
(PV) by approximately 20% and to decrease serum PSA levels 
by about 50% on a 6-month course [7]. It is generally accepted 
that the sensitivity and the specificity of serum PSA levels can 
be maintained by doubling the patient’s PSA value to account 
for the change in PSA [8]. However, this is a rough estimation 
that does not exactly reflect the biological variability in PSA 
between individuals.
 To address these issues, in the present study, various vol-
ume-adjusted PSA parameters were derived and analyzed for 
predictive performance in the detection of PCa. Furthermore, 
in an attempt to investigate whether these volume-adjusted 
indicators may account for the changes in PV, these param-
eters were analyzed and compared between patients who had 
been receiving 5ARIs for over 6 months and patients who were 
naïve to 5ARIs. Our findings indicate that volume-adjusted 
PSA parameters are more reliable than PSA in discriminating 
PCa and that such parameters may reflect changes in prostate 
volumetrics in patients administered 5ARIs.
MATERIALS AND METHODS
1. Patients
The results of 3,520 consecutive prostate biopsies performed 
between May 2006 and January 2013 were retrospectively as-
sessed. The median age of the patients was 67.5 years (range, 
31 to 90 years). The inclusion criteria were patients who un-
Table 1. Clinical characteristics of the overall cohort
Parameter Total Group A Group B P-value
Patients 1,164 291 (25) 873 (75)
Age (yr) 67.5 (31–90) 67.3 (31–90) 67.8 (39–90) 0.474
PSA (ng/mL) 6.5 (2.6–19.8) 6.4 (2.6–19.4) 6.6 (2.7–19.8) 0.707
PSAD 0.15 (0.02–0.75) 0.13 (0.02–0.72) 0.15 (0.02–0.75) 0.001
PV (mL) 43.8 (8.1–263.9) 51.1 (8.1–188.7) 40.1 (12.5–263.9) <0.001
PZV (mL) 18.9 (1.4–93.4) 20.6 (3.4–93.4) 18.1 (1.4–79.1) 0.001
TZV (mL) 23.4 (4.2–184.8) 26.6 (4.7–118.3) 21.3 (4.2–184.8) <0.001
PZPSAD 0.36 (0.04–2.81) 0.39 (0.04–1.54) 0.35 (0.04–2.81) 0.024
TZPSAD 0.26 (0.03–2.32) 0.23 (0.03–1.46) 0.28 (0.03–2.32) 0.001
DRE (+) 209 (17.9) 45 (15.5) 164 (18.8) 0.072
TRUS (+) 141 (12.1) 36 (12.4) 105 (12.1) 0.456
Values are presented as number (%) or median (range).
PSA, prostate-specific antigen; PSAD, PSA density; PV, prostate volume; PZV, peripheral zone volume; TZV, transition zone volume; PZPSAD, peripheral 
zone PSAD; TZPSAD, transition zone PSAD; DRE, digital rectal examination; TRUS, transrectal ultrasonography.
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(22.3%) and in 280 group B patients (32.1%).
2.  Logistic regression analysis on predictive values by 
use of volume-adjusted PSA parameters
Univariate logistic analyses were performed for volume-
adjusted PSA parameters (Table 3). All volume-adjusted PSA 
parameters were significant predictors for the detection of PCa 
in both cohorts. Multivariate regression analysis revealed that 
PSA (odds ratio [OR], 0.959; P=0.021) and PSAD (OR, 84.81; 
P=0.033) were significant independent predictors for detect-
ing PCa for the overall population. In group A, PZPSAD (OR, 
43.18; P = 0.017) remained the only independent predictor, 
whereas in group B, PSA (OR, 0.957; P = 0.038) was an inde-
RESULTS
1. Demographic data of investigated subjects
Among 1,164 eligible patients, group A consisted of 291 pa-
tients (25%), and group B consisted of 873 patients (75%). 
Overall, PCa was histologically diagnosed in 345 patients 
(29.6%). The clinical characteristics of the overall cohort are 
presented in Table 1. Patients in whom PCa was diagnosed 
were older; had higher PSA, PSAD, PZPSAD, and TZPSAD; 
and had significantly lower PV, PZV, and TZV than did patients 
with benign pathology. The clinical characteristics of the 
patients according to group stratification are shown in Table 
2. PCa was histologically confirmed in 65 group A patients 
Table 2. Clinical characteristics of group A (patients on 5ARI) and group B (patients naïve to 5ARI)
Parameter
Group A (n=291) Group B (n=873)
Cancer Benign P-value Cancer Benign P-value
Patients 65 (22.3) 226 (77.7) 280 (32.1) 593 (68.5)
Low grade 30 (46.2) 135 (48.2)
High grade 35 (53.8) 145 (51.8)
Age (yr) 69.3 (51–81) 66.2 (31–90) 0.002 68.5 (39–87) 65.1 (39–90) <0.001
Low grade 69.0 (51–81) 0.186 67.9 (47–80) 0.009
High grade 70.2 (56–81) 0.029 69.8 (39–87) <0.001
PSA (ng/mL) 6.9 (3.3–18.5) 6.3 (2.6–19.4) 0.001 7.0 (3.1–19.5) 6.3 (2.7–19.8) 0.001
Low grade 6.8 (3.3–18.5) 0.376 6.1 (3.1–19.1) 0.498
High grade 8.1 (4.1–17.8) 0.071 8.1 (3.3–19.5) <0.001
PSAD 0.17 (0.04–0.61) 0.12 (0.02–0.72) <0.001 0.18 (0.04–0.75) 0.14 (0.02–0.72) <0.001
Low grade 0.19 (0.06–0.53) 0.002 0.17 (0.04–0.71) 0.052
High grade 0.17 (0.04–0.61) <0.001 0.22 (0.05–0.75) <0.001
PV (mL) 40.1 (8.1–112.7) 53.9 (17.1–188.7) 0.004 36.5 (12.5–146.1) 44.4 (13.6–263.9) <0.001
Low grade 40.4 (15.3–112.7) 0.008 36.9 (12.5–86.1) <0.001
High grade 39.4 (8.1–97.1) 0.002 36.2 (12.7–146.1) 0.002
PZV (mL) 15.6 (3.4–33.9) 21.2 (6.1–93.4) <0.001 16.4 (1.4–44.1) 19.1 (3.6–79.1) <0.001
Low grade 16.2 (8.9–30.7) 0.035 16.2 (1.4–44.1) <0.001
High grade 15.3 (3.4–33.9) <0.001 16.7 (5.9–43.1) <0.001
TZV (mL) 22.7 (4.7–87.7) 30.3 (4.8–118.3) 0.042 20.1 (4.9–103.0) 24.6 (4.2–184.8) 0.001
Low grade 21.9 (6.4–87.7) 0.011 20.7 (6.7–56.1) 0.001
High grade 23.1 (4.7–63.1) 0.002 19.7 (4.9–103.0) 0.021
PZPSAD 0.49 (0.1–1.54) 0.31 (0.04–1.42) 0.001 0.43 (0.11–2.81) 0.32 (0.04–1.95) <0.001
Low grade 0.54 (0.17–1.12) 0.001 0.38 (0.11–2.81) 0.004
High grade 0.42 (0.12–1.54) <0.001 0.51 (0.14–1.88) <0.001
TZPSAD 0.30 (0.07–1.03) 0.22 (0.03–1.46) 0.001 0.37 (0.06–1.46) 0.25 (0.03–2.32) <0.001
Low grade 0.33 (0.09–1.03) 0.011 0.32 (0.06–1.19) 0.025
High grade 0.29 (0.07–1.02) 0.010 0.42 (0.07–1.46) <0.001
DRE (+) 20 (30.8) 25 (11.1) <0.001 93 (33.2) 71 (11.9) <0.001
Low grade 9 (45.0) 39 (41.9)
High grade 11 (55.0) 54 (58.1)
TRUS (+) 22 (33.8) 14 (6.2) <0.001 73 (26.1) 32 (5.4) <0.001
Low grade 13 (59.1) 32 (43.8)
High grade 9 (40.9) 41 (56.2)
Values are presented as number (%) or median (range).
5ARI, 5α-reductase inhibitor; PSA, prostate-specific antigen; PSAD, PSA density; PV, prostate volume; PZV, peripheral zone volume; TZV, transition 
zone volume; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD; DRE, digital rectal examination; TRUS, transrectal ultrasonography.
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pendent parameter (Table 4).
3. Analysis by ROC curves
ROC analyses of volume-adjusted PSA parameters in the 
detection of PCa are shown in Table 5 and Fig. 1. The ROC 
curves of group A showed that PZPSAD had the highest ac-
Table 3. Univariate logistic regression analyses for volume-adjusted PSA parameters of each group
Parameter
Group A Group B
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Age 1.07 1.03–1.11 <0.001 1.06 1.03–1.08 <0.001
PSA 1.03 1.01–1.04 0.011 1.01 1.00–1.02 0.006
PSAD 5.81 2.13–15.78 0.001 2.57 1.63–4.04 <0.001
PZPSAD 2.43 1.47–3.99 <0.001 1.51 1.23–1.83 <0.001
TZPSAD 2.11 1.33–3.34 0.001 1.45 1.19–1.78 <0.001
PSA, prostate-specific antigen; CI, confidence interval; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD.
Table 4. Volume-adjusted PSA parameters which showed sig-
nificant predictive values in multivariate logistic regression 
analyses of each group
Parameter Odds ratio 95% CI P-value
Overall population
PSA 0.959 0.927–0.993 0.021
PSAD 84.81 1.421–5054.7 0.033
Group A
PZPSAD 43.18 1.784–1045.1 0.017
Group B
PSA 0.957 0.917–0.998 0.038
PSA, prostate-specific antigen; CI, confidence interval; PSAD, PSA den-
sity; PZPSAD, peripheral zone PSAD.
Table 5. Receiver operating characteristic curve analyses of 
PSA, PSAD, PZPSAD, and TZPSAD in detecting prostate cancer 
according to each group
Parameter AUC 95% CI
Group A
PZPSAD 0.781 0.712–0.839
PSAD 0.751 0.679–0.811
TZPSAD 0.717 0.645–0.782
PSA 0.677 0.603–0.745
Group B
PZPSAD 0.652 0.614–0.689
PSAD 0.649 0.611–0.686
TZPSAD 0.637 0.598–0.674
PSA 0.582 0.543–0.621
The volume-adjusted PSA parameters are listed the order of their pre-
dictive performance. Group A: PZPSAD vs. PSAD, P=0.038; PSAD vs. TZ-
PSAD, P<0.001; TZPSAD vs. PSA, P=0.554. Group B: PZPSAD vs. PSAD, 
P=0.321; PSAD vs. TZPSAD, P=0.058; TZPSAD vs. PSA, P=0.756.
PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral 
zone PSAD; TZPSAD, transition zone PSAD; AUC, area under the curve; 
CI, confidence interval.
Table 6. Receiver operating characteristic curve analyses of 
PSA, PSAD, PZPSAD, and TZPSAD in detecting high grade can-
cer according to each group
Parameter AUC 95% CI
Group A
PZPSAD 0.625 0.487–0.731
PSAD 0.614 0.476–0.742
TZPSAD 0.601 0.462–0.731
PSA 0.562 0.425–0.695
Group B
PSA 0.715 0.647–0.776
PSAD 0.667 0.597–0.731
PZPSAD 0.662 0.593–0.727
TZPSAD 0.661 0.591–0.726
The volume-adjusted PSA parameters are listed the order of their pre-
dictive performance. Group A: PZPSAD vs. PSAD, P=0.716; PSAD vs. TZ-
PSAD, P =0.581; TZPSAD vs. PSA, P =0.038. Group B: PSA vs. PSAD, 
P=0.041; PSAD vs. PZPSAD, P=0.803; PZPSAD vs. TZPSAD, P=0.956.
PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral 
zone PSAD; TZPSAD, transition zone PSAD; AUC, area under the curve; 
CI, confidence interval.
curacy for discriminating PCa, followed by PSAD, TZPSAD, 
and PSA. PSAD and PZPSAD revealed significantly higher 
AUCs than that of PSA, whereas the superiority of PZPSAD 
compared with PSAD was statistically significant (P = 0.039). 
The sensitivities of the two highest predictors, i.e., PSAD and 
PZPSAD, at a set specificity of 40%, were 84% and 88%, respec-
tively. In group B, PSAD and PZPSAD showed significantly 
higher AUCs than did PSA (P<0.001); however, the AUC of PZ-
PSAD failed to significantly surpass that of PSAD (P=0.321). 
TZPSAD showed no better accuracy than PSA. The sensitivi-
ties of the two highest predictors, i.e., PSAD and PZPSAD, at a 
set specificity of 40%, were 81% and 79%, respectively.
 ROC analyses of volume-adjusted PSA parameters in de-
tecting high-grade PCa are shown in Table 6 and Fig. 2. PZ-
PSAD revealed the highest AUC in group A but did not meet 
statistical significance compared with PSAD, which revealed 
the second highest AUC. A notable finding was that PSA was 
significantly inferior to all volume-adjusted parameters for 
detecting PCa. The sensitivities of the two highest predictors, 
Koo, et al. Significance of peripheral zone PSAD
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i.e., PSAD and PZPSAD, at a set specificity of 40%, were 85% 
and 87%, respectively. In group B, PSA showed the highest 
AUC for discriminating high-grade disease. The sensitivity of 
PSA at 40% specificity was revealed to be 76%. 
DISCUSSION
It is generally accepted that PSA provides the highest diag-
nostic performance for PCa and that its application to clinical 
practice has revolutionized the management of this disease 
[2]. However, the major drawback is its lack of cancer speci-
ficity and the lack of an upper or lower threshold value [9,10]. 
False elevations in noncancerous conditions not only result in 
unnecessary biopsies that lead to potential complications, but 
often mask aggressive forms of cancer that may lead to sub-
stantial harm [1]. This ongoing clinical challenge has aroused 
scientific challenges to evaluate novel biomarkers sensitive to 
PCa, namely, genetic-based, serologic, and urinary markers 
[11]. However, to date, none of these biomarkers has clearly 
outweighed diagnostic benefits against drawbacks. The pres-
ent study did not seek to settle these concerns, but to raise the 
possibility that controlling for confounding conditions that 
Fig. 1. Receiver operating characteristic curves comparing the performances of PSA, PSAD, PZPSAD, and TZPSAD in the detection of 
prostate cancer in group A (A) and group B (B). The receiver-operating characteristic area under the curve and comparisons of each pa-
rameter are shown in Table 5. PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition 
zone PSAD.
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Fig. 2. Receiver operating characteristic curves comparing the performances of PSA, PSAD, PZPSAD, and TZPSAD in the detection of 
high-grade cancer in group A (A) and group B (B). The receiver-operating characteristic area under the curve and comparisons of each 
parameter are shown in Table 6. PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition 
zone PSAD.
100
80
60
40
20
0
100
80
60
40
20
0
 0 20 40 60 80 100  0 20 40 60 80 100 
Se
ns
iti
vi
ty
Se
ns
iti
vi
ty
PSA
PSAD
PZPSAD
TZPSAD
PSA
PSAD
PZPSAD
TZPSAD
100-Specificity 100-SpecificityA B
Vol. 1 / No. 3 / September 2013
107
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.13022
can affect PSA values, such as benign prostatic enlargement, 
may confer additional diagnostic value. Indeed, developing 
a strategy of utilizing clinical parameters that are routinely 
evaluated, i.e., serum PSA and PV measurement by TRUS, 
could be of benefit in terms of cost, time, and treatment deci-
sion making.
 The present study utilized volume-adjusted PSA-based 
parameters in an attempt to enhance the predictive perfor-
mance of PSA. Kalish et al. [12] first introduced the concept of 
utilizing the volume-adjusted PSA-based parameter TZPSAD 
to show its superiority in discriminating PCa compared with 
PSAD. Validation studies have been performed by Kang et al. 
[13] showing that TZPSAD may be more effective in patients 
with intermediate PSA levels. Furthermore, Djavan et al. [14] 
reported that TZPSAD was more useful in patients with pros-
tates larger than 30 g. However, Tanaka et al. [15], along with 
several other studies, showed that TZPSAD has an AUC simi-
lar to that of PSAD and disproved the usefulness of TZPSAD.
 Alongside these investigations, our study is the first of its 
kind to utilize PZPSAD in addition to PSAD and TZPSAD as 
a potential predictive indicator for PCa and to compare these 
indexes between groups stratified according to 5ARI adminis-
tration. We demonstrated that TZPSAD has a similar predic-
tive value to PSAD in patients naïve to 5ARI and that its value 
is significantly below the level of PSAD in patients receiving 
5ARIs. We further demonstrated that PZPSAD, among all vol-
ume-adjusted PSA parameters, had the significantly highest 
predictive value for detecting PCa in the 5ARI administration 
group. PZPSAD was also shown to be the most useful in the 
5ARI-naïve group; however, it did not reach significance. In 
line with previous studies, PSA showed the lowest AUC com-
pared with volume-adjusted PSA parameters.
 The effectiveness of PSA and PSAD in detecting high-grade 
PCa (herein defined as a Gleason score sum ≥7) has been con-
troversial. Elliot et al. [16] reported a trend toward improved 
performance of PSA for both Gleason ≥ 7 and Gleason ≥ 8 
diseases. Our study is consistent with previous results show-
ing that PSA demonstrates the highest AUC for predicting 
high-grade PCa in patients naïve to hormonal manipulation 
[17]. However, our study demonstrated the novel finding that 
in patients administered 5ARIs, the AUC for PSA falls signifi-
cantly below that for all other volume-adjusted PSA param-
eters.
 A logical question that could be raised by our findings is, 
“Why would PZPSAD be a better indicator for PCa in patients 
administered 5ARIs?” A possible answer is that patients re-
ceiving 5ARIs would have larger PV and higher PSA levels 
owing to the relative enlargement of TZV. To the best of our 
knowledge, no study to date has investigated changes in dif-
ferential prostate zonal volumes in patients administered 
5ARIs. However, it can be presumed that 5ARI has a relatively 
greater effect on the reduction of TZV and a modest effect 
on PZV, because TZ accounts for a greater proportion of the 
total PV in benign prostatic enlargement [18]. This volume 
reduction effect may have suppressed PSA owing to benign 
prostatic hyperplasia and thus led to a greater separation in 
PZPSAD values compared with values in those who actually 
harbored PCa. Indeed, PCa detected by a conventional PZ 
biopsy scheme as used in the present study would mostly re-
flect PZ cancers rather than TZ cancers. To clearly define the 
underlying mechanisms of these observations, investigations 
on relative zonal volume reductions according to administra-
tion of 5ARI should be undertaken.
 The present study had several limitations that should be 
mentioned. First, the study was retrospective in nature. To 
confirm our findings, prospective and randomized studies 
with larger populations will be needed. Second, we could not 
exactly determine whether a patient harbors PCa because a 
prostate biopsy may miss 20% of PCa considered to be clini-
cally significant and, conversely, may detect insignificant 
cancers [19,20]. Third, volume-adjusted PSA measurements 
necessitate PV determinations that are not always available 
in clinical practice. Last, our study cohort was not based on a 
general population as a whole but on a database of patients 
obtained from a single, tertiary institution. Therefore, our 
results may include a selection bias in which the results may 
not be applicable to the whole population.
 In conclusion, volume-adjusted PSA parameters could be 
more useful than PSA in detecting PCa. For patients receiving 
5ARI for more than 6 months, PZPSAD conferred the highest 
diagnostic performance in predicting PCa and high-grade 
disease. In patients naïve to 5ARIs, PSA remained superior 
to PSAD or PZPSAD in predicting high-grade disease but 
showed the lowest value for discriminating PCa.
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